1488P - Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC)

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Soft Tissue Sarcomas
Presenter Angela Pang
Citation Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387
Authors A. Pang1, R. Ngan2, S.H. Tan3, T. Hirose4, M. Endo5, M. Farid6, W.L. Goh6, H.H. Loong7, S. Mingmalairak8, C. Chang9, S. Teo10, M.M. Maw11, A.K.C. Leung2, J.C. Chan12, M.E. Puhaindran13, A. Kawai4, T.W. Chen14, R. Quek6, V. Sriuranpong8
  • 1Department Of Haematology-oncology, National University Cancer Institute, National University Health System, 119074 - Singapore/SG
  • 2Department Of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong/HK
  • 3Division Of Clinical Trials And Epidemiological Sciences, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 4Division Of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo/JP
  • 5Department Of Orthopaedic Surgery, Kyushu University, Fukuoka/JP
  • 6Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 7Department Of Clinical Oncology, The Chinese University of Hong Kong, 00000 - Hong Kong/HK
  • 8Division Of Medical Oncology, Department Of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok/TH
  • 9Department Of Cancer Administration And Coordination Center, National Taiwan University Hospital, Taipei/TW
  • 10Department Of Haematology-oncology, National University Cancer Institute, National University Health System, Singapore/SG
  • 11Medical Oncology Unit, University of Medicine 1, Yangon, Yangon/MM
  • 12Department Of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR/HK
  • 13Department Of Hand And Reconstructive Microsurgery, National University Hospital, Singapore/SG
  • 14Department Of Oncology, National Taiwan University Hospital, 100 - Taipei/TW



We previously reported on the real world treatment and outcomes of 423 angiosarcoma pts in Asia. In this current report, we focus on the 173 pts with V-AS and evaluate the treatment patterns and prognostic factors associated with this disease subset.


This is a retrospective chart review of V-AS pts seen at 8 Asian academic study sites. Survival analysis is measured from date of presentation to the study site.


Median study follow-up was 8.7 mths. Median age 52 yrs; 86% of pts presented with primary disease to study site. 42% (n = 73) had localized disease and 56% (n = 97) had locally advanced/unresectable or metastatic disease; disease status was unknown for 3 pts. Distribution of primary site as follows, liver (n = 38, 22%), cardiovascular system (n = 30, 17%), breast (n = 25, 14%), spleen (n = 18, 10%) and others (n = 62, 36%) from a myriad of organ systems each representing  3 lines of treatment respectively. The most common first line chemotherapy used was paclitaxel (53%) followed by liposomal doxorubicin (18%). Median OS was 11.9 mths in the overall V-AS cohort, with median OS 29.2 mths and 6.3 mths in the localized and advanced/unresectable cohort respectively. In the univariate analysis of pts with unresectable/metastatic disease, only ECOG was associated with OS.


This study highlights the heterogeneity and treatment challenges of visceral angiosarcoma. Overall prognosis is poor, in particular in pts with advanced/unresectable disease.

Clinical trial identification


Legal entity responsible for the study

National Cancer Centre Singapore




R. Quek: Grants/research support: Novartis, Pfizer, Janssen, Bayer and Eisai. Honoraria/consultation fees: Novartis, Bayer, BMS, Merck, Roche and Eisai. Participation in a company sponsored speaker\'s bureau: Novartis, Bayer, Merck and Eisai. All other authors have declared no conflicts of interest.